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Abstract
Background: In high human immunodeficiency virus (HIV) prevalence population, tuberculosis (TB) is the leading
cause of morbidity and mortality. HIV is driving the TB epidemic in many countries, especially those in sub-Saharan
Africa. We assessed the survival time and predictors of mortality among tuberculosis patients under directly
observed treatment, short course (DOTS) strategy in Dessie Referral Hospital tuberculosis clinic, Northeast Ethiopia.
Method: A historical cohort design was utilized to assess survival time and determinants of mortality. A total of
1260 records of patients who started ant-tuberculosis treatment from January 2006 up to December 2010 were
analyzed. Survival curves were estimated using Kaplan–Meier and were compared using the Log-rank test. The Cox
proportional hazard model was used to assess the relationship between baseline variables and mortality.
Results: Out of the 1260 registered patients, 117 (9.3 %) died over the entire follow-up period. Among those died,
113 (18 %) were HIV positive and 4 (0.6 %) were HIV negative. The 1260 patients contributed a cumulative total of
634.25 person‑years observation.
Conclusion: The mortality of HIV positive tuberculosis patients was higher than those of HIV negative patients and
the use of cotrimoxazole preventive therapy increased the survival time of patients.
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Background
Tuberculosis (TB) remains a major global health prob-
lem. It causes ill-health among millions of people each
year and ranks as the second leading cause of death
from an infectious disease worldwide, after HIV. In
2014, 6 million new cases of TB were reported to the
World Health Organization (WHO) and TB killed 1.5
million people (1.1 million HIV-negative and 0.4 million
HIV-positive). Despite the fact that nearly all cases can
be cured, TB remains one of the world’s biggest threats
[1]. The synergy between TB and HIV is strong; in high
HIV prevalence population, TB is a leading cause of
morbidity and mortality, and HIV is driving the TB
epidemic in many countries, especially those in sub-
Saharan Africa [2].
Ethiopia is one of the 22 high burden countries and
TB remains one of the leading causes of mortality.
According to the 2014 WHO report, the prevalence and
incidence of all forms of TB are 211 and 224 per
100,000 of the population, respectively. Excluding HIV
related deaths, in 2013 TB mortality was estimated to be
32 per 100,000 of the population. About 13 % of all new
TB cases are also HIV co-infected. Moreover, Ethiopia is
one of the high TB/HIV burden countries. Among TB
patients with known HIV status, about 11 % were HIV
co-infected [1].
In Ethiopia a standardized TB prevention and control
programme, incorporating Directly Observed Treatment,
Short Course (DOTS), was started in 1992. The DOTS
strategy has been subsequently scaled up in the country
and implemented at national level [3]. The scale of the
global TB epidemic demands urgent and effective action.
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as early as possible and to ensure that those diagnosed
complete their treatment and get cured [4].
In 1995, WHO set a target of 85 % treatment success
among new sputum smear-positive cases [4]. Identifica-
tion of factors for treatment failure is important in redu-
cing TB spread, morbidity and mortality in affected
individuals and may help in contributing to the achieve-
ment of the treatment targets.
Understanding the predictors of mortality for TB-HIV
co-infected patients in the local context is critical for
Ethiopia to improve TB-HIV co-infected patients’ co-
management. The survival time of TB patients can be
affected by different factors. Studies showed that
antiretroviral therapy (ART) status, cotrimoxazole pre-
ventive therapy (CPT) status and type of TB diagnosis
were independent predictors of mortality. Initiation of
ART and CPT as well as extra pulmonary TB type de-
creased risk of mortality in TB/HIV co-infected individ-
uals [5]. In resource-poor settings limited data exist both
on treatment results and on how to carry out such inter-
ventions. As a result, the existing treatment guidelines
and recommendations are based on data from the devel-
oped world. Studying the survival patterns will help in
identifying the risk factors for mortality in these patients
and planning effective interventions to further reduce
death rates. Therefore, the aim of this study was to as-
sess the survival time and predictors of mortality among
TB patients under DOTS strategy in Dessie Referral
Hospital (DRH) TB clinic, Northeast Ethiopia.
Methods
The study was conducted in DRH TB clinic, Northeast
Ethiopia from January 1–30, 2014. DRH has a catchment
population of seven million and has a total bed size of 200
with 185 health professionals (13 specialists, 14 general
practitioners, 3 health officers, 6 anesthetists, 99 nurses, 12
midwifes, 12 pharmacy professionals, 12 medical laboratory
professionals, 5 X-ray technicians and 2 environmental
health professionals. The TB clinic is one of the hospital
segments serving 300 patients on average per annum.
A historical cohort design was utilized to assess
survival time and predictors mortality. Based on HIV
status, TB patients was categorized into “HIV positive”
and “HIV negative” cohorts and were retrospectively
followed until the time of the outcome (death) or
censoring. Survival time was measured from the date of
initiation of therapy to death or to the last follow-up.
Individuals who died were considered as failures, those
who remained alive until the end of the treatment or
dropped out were considered as censored. A total of
1260 out of 1375 patient record cards of TB patients
who started ant-TB treatment from January 2006 up to
December 2010 in DRH TB clinic were included and
retrospectively followed for an additional one year.
The independent variables were age, sex, residence,
baseline weight, HIV status, type of TB, and CPT. The
outcome variable was survival time.
Structured questionnaire developed using standardized
TB entry and follow up form employed by the TB clinic
was utilized to extract the required data from patient
records. The data was collected by reviewing registers,
follow up form and patients’ card. Two nurses working
at the TB clinic of DRH were recruited and trained
about methods of data collection for two days. Data
quality was controlled by designing the proper data
collection materials and through continuous supervision.
All completed data collection forms were examined for
completeness and consistency during data management
and analysis. The data was entered and cleaned by a data
clerk and the principal investigator before analysis.
The survival time was calculated using the time
interval between the date of anti-TB initiation and the
date of event (death) or censoring. The Kaplan-Meier
model was used to estimate the survival probability after
anti-TB initiation, and the Log-rank test was used to
compare survival curves. The Cox proportional hazard
model was used to assess the relationship between base-
line variables and mortality. Descriptive statistics and
Cox regression were conducted using SPSS version 16.
Ethical clearance was obtained from College of Medicine
and Health Sciences, Wollo University Institutional
Review Committee (IRC), and permission was sought
from DRH.
Results
Demographic and clinical characteristics
In this retrospective document analysis from January
2006 up to December 2010, socio-demographic and
medical information of 1260 registered TB patients was
summarized. Out of the total study participants
781(62 %) were males and 1206 (95.7 %) were from
urban areas. Half (50.1 %) of the study subjects were
HIV negative, 16.4 % were smear positive pulmonary
TB, 39.8 % were smear negative pulmonary TB and
43.7 % were extra pulmonary TB patients. Majority of
the study participants (83.6 %) were new cases (Table 1).
Survival status of the study subjects
Of 629 HIV positive and 631 HIV negative TB patients,
113 (18 %) of the HIV positive and 4 (0.6 %) of the HIV
negative died and were treated as failure in the analysis.
The remaining 516 (82.0 %) HIV positive and 627 (99.4 %)
HIV negative patients became censored during the follow
up period (Table 1). The 1260 patients contributed a
cumulative total 634.25 person‑years observation, which
gave rise to the overall mortality rate of 18.4 per 100
person-years of follow up per annum (117 died over the
entire person-years of follow up). The median and the
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mean survival times were 210 and 183.7 days, respectively.
The log-rank test was conducted to check for existence of
any significant differences in survival experience among
various levels of the categorical variables included in the
study. The result in Fig. 1 manifest a significant (Log rank
test = 112.423, p < 0.001) differences among HIV positive
and HIV negative cohorts.
Predictors of mortality
The relationship between the main baseline variables and
the risk of death was analyzed using a Cox proportional
hazard regression model. The result showed that gender,
age, residence, weight, CPT, type of TB and HIV status
were all significantly associated with death of TB patients
during the period of TB treatment (Table 2). Compared to
HIV positive patients, the hazard ratio (HR) of dying from
TB decreased significantly by 99 % in HIV negative TB
patients; adjusted hazard ration (AHR) = 0.01, 95 % CI:
[0.003, 0.027]. Mortality risk among female TB patients
increases significantly by about two fold compared to
males; AHR = 2.360, 95 % CI: [1.518, 3.671]. According to
the result the risk of dying significantly reduced in patients
receiving CPT by 76.6 % compared to those not receiving
CPT; AHR = 0.234, 95 % CI: [0.145, 0.377].
Discussion
WHO defines TB mortality as the number of TB cases
dying during treatment, regardless of the cause. Death
caused by TB is preventable and management can be
modified at the time of highest risk for death if known
[6]. It is now recognized that both TB and HIV contrib-
ute to each other’s progress. Patients co-infected with
TB and HIV have higher mortality rates in comparison
with those infected with one or the other. In several case
series, the main predictor for survival was the prompt
initiation of effective anti-tuberculosis treatment, ART,
CD4 count, site of the disease, and other previous or
concurrent opportunistic infections caused by immuno-
suppression [7–9].
Of the 1260 registered patients, 117 (9.3 %) died over
the entire follow-up period. The mortality in our study
was higher than the report in Addis Ababa, Ethiopia [10]
and the nationwide mortality in Ethiopia [3], but lower
than those reported in previous studies including 10.0 %
in Gondar, Ethiopia [11], and 14 % in Vaud County,
Switzerland [12]. Similarly, the study has demonstrated
significant difference on the prevalence of death between
HIV positive and HIV negative TB patients. Of 629 HIV
positive and 631 HIV negative TB patients, 113 (18 %) of
the HIV positive and 4 (0.6 %) of the HIV negative died.
Similar to the current study, previous studies [13]
reported higher overall death rates among HIV positive
TB patients than HIV negative TB patients.
HIV infection is the primary reason for the failure to
meet tuberculosis control targets (at least 85 % cure rate
among new sputum smear positive TB cases) in countries
with high HIV infection. This is attributable to factors such
as over diagnosis of sputum smear negative TB, under
diagnosis of sputum smear-positive TB, low cure rates, high
morbidity, mortality and default rates during treatment,
and atypical clinical presentation of TB in HIV infected
patients. Consequently, HIV infection leads to diagnostic
Table 1 Baseline characteristics of TB patients treated at DRH
from January 2006 – December 2010
Variables HIV status Total
Positive (n = 629) Negative (n = 631)
Gender
Male 341 (54.2) 440 (69.7) 781 (62.0)
Female 288 (45.8) 191 (30.7) 479 (38.0)
Age group
< 20 83 (13.2) 80 (12.7) 163 (12.9)
20–29 110 (17.5) 288 (45.6) 398 (31.6)
30–39 274 (43.6) 148 (23.5) 422 (33.5)
40–49 101 (16.1) 36 (5.7) 137 (10.9)
> 49 61 (9.7) 79 (12.5) 140 (11.1)
Residence
Urban 600 (95.4) 606 (96.0) 1206 (95.7)
Rural 29 (4.6) 25 (4.0) 54 (4.3)
Baseline weight
< 20 43 (6.8) 31 (4.9) 74 (5.9)
20–29 16 (2.5) 3 (0.5) 19 (1.5)
30–39 45 (7.2) 63 (10.0) 108 (8.6)
40–49 195 (31.0) 136 (21.6) 331 (26.3)
> 49 330 (52.5) 398 (63.1) 728 (57.8)
CPT initiated
No 186 (29.6) 581 (92.1) 767 (60.9)
Yes 443 (70.4) 50 (7.9) 493 (39.1)
ART initiated
No 348 (55.3) 631 (100) 979 (77.7)
Yes 281 (44.7) 0 (0.0) 281 (22.3)
Type of TB
Smear positive 67 (10.7) 140 (22.2) 207 (16.4)
Smear negative 291 (46.3) 211 (33.4) 502 (39.8)
EPTB 271 (43.1) 280 (44.4) 551 (43.7)
Treatment category
New 539 (85.7) 514 (81.5) 1053 (83.6)
Retreatment 90 (14.3) 117 (18.5) 207 (16.4)
Patient status
Censored 516 (82.0) 627 (99.4) 1143 (90.7)
Died 113 (18.0) 4 (0.6) 117 (9.3)
CPT Cotrimoxazole preventive therapy, ART Antiretroviral therapy, TB
Tuberculosis, EPTB-Extrapulmonary TB
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challenges and delays in identifying TB that profoundly
impacts treatment outcome [14].
The relationship between the main baseline variables
and the risk of death was analyzed using a Cox propor-
tional hazard regression model. In our study not initiat-
ing CPT was associated with high risk of mortality. In
line with this, studies from Northwest Ethiopia [5] South
India [15] and Sub-Saharan Africa [16] showed that not
taking CPT was significantly associated with mortality.
CPT is a simple well tolerated and cost effective inter-
vention which can extend and improve the quality of life
for people living with HIV/AIDS including those on
ART. CPT is associated with a 25–46 % reduction in
mortality among individuals infected with HIV in sub-
Saharan Africa even in areas of high bacterial resistance
to the antibiotic [17, 18].
Previous studies found that TB-HIV co-infected
patients who took ART during TB treatment had a lower
risk of death. They also demonstrate the positive impact
of ART on the survival outcomes among TB-HIV co-
infected patients, including successful immune restor-
ation and reductions in morbidity and mortality [5, 19].
In our study we did not find any significant difference in
mortality between the on ART and non-ART cohorts,
which is in agreement with previous studies [13]. This
might be associated with delayed initiation of ART. The
optimal time to initiate ART in patients with HIV-
associated tuberculosis has been the subject of intense
debate. Concerns about early initiation of ART include a
high pill burden, pharmacological interactions, overlap-
ping toxicities and the immune reconstitution inflamma-
tory syndrome (IRIS) [20]. Conversely, delayed initiation
of ART may be associated with HIV disease progression
and death [21]. Previous retrospective studies [22, 23]
showed that delaying ART initiation until after comple-
tion of TB therapy was associated with increased
mortality.
Previous TB treatment and multiple drug‑resistant TB
(MDR‑TB) are considered significant risk factors for
decease. It is known that patients previously treated for
TB have a higher risk of presenting MDR TB and of
dying than new TB patients [24]. There are also reports
supporting the idea that failure or relapses were not
associated with an increased risk of death [25]. This
study also adds to the literature that treatment category
(new or retreatment) was not significantly associated
with mortality in the adjusted model, this might be due
to late presentation of patients to the hospital and
advanced disease progress.
Our study was done retrospectively to find out the
common risk factors associated with mortality that was
considered one of the limitations of the survey. The data
have been extracted from medical records of patients who
have been already visited and registered at the hospital, so
it may be subjected to selection bias. The other limitation
of the survey was the fact that in many TB patients,
multiple causes of death may act simultaneously, so the






















Fig. 1 Survival curve by HIV status of TB patients (n = 1260) treated at DRH from January 2006 – December 2010. Statistical analysis was done using
the Kaplan-Meier model to estimate the survival probability after anti-TB initiation, and the Log rank test was used to assess the relationship between
HIV status and mortality. The result showed that the survival time in days of HIV negative cohorts was significantly (Log rank test = 112.423, p < 0.001)
higher than those of HIV positive cohorts. Statistical significance was set at p < 0.05
Beyene et al. BMC Public Health  (2016) 16:883 Page 4 of 6
Conclusions
In summary, results from this study indicate that the
mortality of HIV positive TB patients was higher than
those of HIV negative TB patients and use of CPT can
prolong the survival time of TB patients. The decrease
in mortality among TB/HIV patients requires public
health interventions and the enhancement of existing
control programs to improve both prevention and treat-
ment. Interventions should be directed at modifiable risk
such as treatment of opportunistic infections.
Acknowledgements
We are very grateful to all members working in DRH TB clinic for their
assistance in this study.
Funding
This research received no specific grant from any funding agency in the
public, commercial or not-for-profit sectors.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article.
Authors’ contributions
All have been involved in the design and conceptual framework of the
study. BG worked on analyzing the data; YB was involved in drafting the
manuscript, and the role of AM was crucial in data collection and




The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was approved by the Institutional Review Committee (IRC) of
Wollo University.
Author details
1Department of Nursing, College of Medicine and Health Sciences Wollo
University, Dessie, Ethiopia. 2Department of Pharmacy, College of Medicine
and Health Sciences, Wollo University, Dessie, Ethiopia.
Received: 26 September 2015 Accepted: 19 August 2016
References
1. World Health Organization. Global Tuberculosis control report. 20th ed.
Geneva: WHO; 2015.
2. Federal Minister of Health. Implementation Guideline for TB/HIV Collaborative
Activities in Ethiopia. Addis Ababa: Federal Ministry of Health; 2007.
3. Federal Ministry of Health. Guidelines for clinical and programmatic
management of TB, TB/HIV and leprosy in Ethiopia. 5th ed. Addis Ababa:
Federal Ministry of Health; 2012.
4. World Health Organization. Treatment of tuberculosis: Guidelines for
National Programmes. 4th ed. Geneva: WHO; 2010.
5. Sileshi B, Deyessa N, Girma B, Melese M, Suarez P. Predictors of mortality
among TB-HIV Co-infected patients being treated for tuberculosis in
Northwest Ethiopia: a retrospective cohort study. BMC Infect Dis.
2013;13:297.
6. World Health Organization. Framework for effective tuberculosis control.
Geneva: WHO; 1994.
7. Ackah AN, Coulibaly D, Digbeu H, Diallo K, Vetter KM, Coulibaly IM,
Greenberg AE, De Cock KM. Response to treatment, mortality, and CD4
lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan,
Cote d’Ivoire. Lancet. 1995;345:607–10.
8. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J.
Accelerated clinical course of HIV infection after tuberculosis. Am J Respir
Crit Care Med. 1995;151:129–35.
9. Shafer RW, Bloch AB, Larkin C, Vasudavan V, Seligman S, Dehovitz JD,
DiFerdinando G, Stoneburner R, Cauthen G. Predictors of survival in HIV-
infected tuberculosis patients. AIDS. 1996;10:269–72.
Table 2 Predictors of mortality among TB patients treated at
DRH from January 2006 – December 2010
Variables Status Adjusted hazard




Male 727 54 1
Female 416 63 2.360 (1.518, 3.671)a 0.000
Age group
< 20 129 34 1
20–29 366 32 1.317 (0.629, 2.755) 0.465
30–39 401 21 0.335 (0.156, 0.722)a 0.005
40–49 120 17 1.029 (0.442, 2.394) 0.948
> 49 127 13 1.687 (0.649, 4.385) 0.283
Residence
Urban 1114 92 1
Rural 29 25 4.230 (2.508, 7.136)a 0.000
Baseline weight
< 20 54 20 1
20–29 19 0 0.000 (0.000, 0.000) 0.957
30–39 99 9 1.103 (0.420, 2.894) 0.843
40–49 291 40 0.811 (0.332, 1.980) 0.646
> 49 680 48 0.389 (0.178, 0.851)a 0.018
HIV status
Positive 516 113 1
Negative 627 4 0.010 (0.003, 0.027)a 0.000
CPT initiated
No 688 79 1
Yes 455 38 0.234 (0.145, 0.377)a 0.000
ART initiated
No 891 88 1
Yes 252 29 0.694 (0.414, 1.163) 0.166
Type of TB
Smear positive 192 15 1
Smear negative 472 30 0.417 (0.207, 0.837)a 0.014
EPTB 479 72 1.149 (0.595, 2.222) 0.679
Treatment category
New 944 109 1
Retreatment 199 8 0.438 (0.191, 1.005) 0.051
CPT Cotrimoxazole preventive therapy, ART-Antiretroviral therapy, TB
Tuberculosis, EPTB Extrapulmonary TB
aSignificant at α = 0.05
Beyene et al. BMC Public Health  (2016) 16:883 Page 5 of 6
10. Getahun B, Ameni G, Biadgilign S, Medhin G. Mortality and associated risk
factors in a cohort of tuberculosis patients treated under DOTS programme
in Addis Ababa, Ethiopia. BMC Infect Dis. 2011;11:127.
11. Tessema B, Muche A, Bekele A, Reissig D, Emmrich F, Sack U. Treatment
outcome of tuberculosis patients at Gondar University Teaching Hospital,
Northwest Ethiopia. A five - year retrospective study. BMC Publ Health.
2009;9:371.
12. Zellweger JP, Coulon P. Outcome of patients treated for tuberculosis in
Vaud County, Switzerland. Int J Tuberc Lung Dis. 1998;2:372–7.
13. Shaweno D, Worku A. Tuberculosis treatment survival of HIV positive TB
patients on directly observed treatment short-course in Southern Ethiopia:
A retrospective cohort study. BMC Res Notes. 2012;5:682.
14. Mahajan V, Verma SK. HIV-Tuberculosis co-infection. The Internet Journal of
Pulmonary Medicine 2008, http://www.ispub.com Accessed Jul 12 2013.
15. Vijay S, Kumar P, Chauhan LS, Narayan Rao SV, Vaidyanathan P. Treatment
outcome and mortality at one and half year follow-Up of HIV infected TB
patients under TB control programme in a District of South India. PLoS One.
2011;6:e21008.
16. Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected
tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc
Lung Dis. 2009;13:6–16.
17. Badri M, Ehrlich R, Wood R, Maartens G. Initiating co-trimoxazole prophylaxis
in HIV-infected patients in Africa: an evaluation of the provisional WHO/
UNAIDS recommendations. AIDS. 2001;15:1143–8.
18. World Health Organization. Guideline on cotrimoxazole prophylaxis for HIV
related infections among children, adolescent & adults. 2nd ed. Geneva:
WHO; 2009.
19. Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, Srinak
C, Nateniyom S, Sattayawuthipong W, Tasaneeyapan T, Varma JK. Causes of
death in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect
Dis. 2009;15:258–64.
20. Stockdale AJ, Nkuranga J, Török ME, Faragher B, Lalloo DG. Initiation of
Antiretroviral Therapy in HIV-Infected Tuberculosis Patients in Rural Kenya:
An Observational Study. Trop Med Int Health. 2013;18:907–14.
21. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr
Opin HIV AIDS. 2009;4:325–33.
22. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A,
Sungkanuparph S. Survival rate and risk factors of mortality among HIV/
tuberculosis coinfected patients with and without antiretroviral therapy.
J Acquir Immune Defic Syndr. 1999;43:42–6.
23. Velasco M, Castilla V, Sanz J, Gaspar G, Condes E, Barros C, Cervero M, Torres
R, Guijarro C. Effect of simultaneous use of highly active antiretroviral
therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic
Syndr. 1999;50:148–52.
24. Tocque K, Convrey RP, Bellis MA, Beeching NJ, Davies PD. Elevated mortality
following diagnosis with a treatable disease: tuberculosis. Int J Tuberc Lung
Dis. 2005;9:797–801.
25. Lefebvre N, Falzon D. Risk factors for death among tuberculosis cases:
analysis of European surveillance data. Eur Respir J. 2008;31:1256–60.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Beyene et al. BMC Public Health  (2016) 16:883 Page 6 of 6
